DOCSLIB.ORG

Sample Thesis Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sample Thesis Template The Clinical Manifestations and Molecular Mechanisms of Mitochondrial Neuro-Ophthalmological Disorders Patrick Yu Wai Man BMedSci (Hons), MBBS (Hons), MRCOphth Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the Faculty of Medical Sciences 2010 I To Mum, Dad and Cynthia I Table of Contents LIST OF TABLES.....................................................................................................VII LIST OF FIGURES..................................................................................................VIII ABSTRACT.................................................................................................................IX ACKNOWLEDGEMENTS.......................................................................................XII AUTHOR’S DECLARATION................................................................................XIV ABBREVIATIONS....................................................................................................XV CHAPTER 1 INTRODUCTION ................................................................................. 1 1.1 THE MITOCHONDRION ........................................................................................... 2 1.1.1 Evolutionary Origin ....................................................................................... 2 1.1.2 Mitochondrial Structure ................................................................................. 2 1.1.3 Oxidative Phosphorylation ............................................................................. 4 1.2 MITOCHONDRIAL GENETICS ................................................................................... 8 1.2.1 Mitochondrial DNA ....................................................................................... 8 1.2.2 Mitochondrial Haplogroups ........................................................................... 9 1.2.3 Mitochondrial DNA Mutations .................................................................... 11 1.2.4 Mitochondrial Heteroplasmy ....................................................................... 11 I 1.2.5 Threshold Effect ........................................................................................... 12 1.3 MITOCHONDRIAL INHERITANCE ........................................................................... 13 1.3.1 Maternal Transmission ................................................................................. 13 1.3.2 Mitochondrial Bottleneck ............................................................................ 13 1.4 MITOCHONDRIAL DNA MAINTENANCE ............................................................... 16 1.4.1 Mitochondrial Nucleoids ............................................................................. 16 1.4.2 Mitochondrial DNA Replication .................................................................. 17 1.4.3 Mitochondrial Nucleotide Pools .................................................................. 20 1.4.4 Regulation of MtDNA Copy Number .......................................................... 22 1.5 MITOCHONDRIAL TRANSCRIPTION ....................................................................... 23 1.6 MITOCHONDRIAL TRANSLATION .......................................................................... 24 1.7 SOMATIC MTDNA ABNORMALITIES .................................................................... 26 1.7.1 Ageing .......................................................................................................... 26 1.7.2 Polg Mouse Models ..................................................................................... 27 1.7.3 Cancer .......................................................................................................... 28 1.7.4 Nuclear Mitochondrial Disorders ................................................................ 29 1.8 MITOCHONDRIAL DNA DELETIONS ..................................................................... 31 1.8.1 Formation ..................................................................................................... 31 1.8.2 Clonal Expansion ......................................................................................... 34 1.9 MITOCHONDRIAL DYNAMICS ............................................................................... 36 1.9.1 Fusion and Fission ....................................................................................... 36 II 1.9.2 MFN1 and MFN2 ........................................................................................ 37 1.9.3 OPA1 ............................................................................................................ 39 1.9.4 DRP1 and hFIS1 .......................................................................................... 40 1.9.5 Mitochondrial Membrane Proteases ............................................................ 42 1.9.6 Reactive Oxygen Species ............................................................................. 43 1.9.7 Apoptosis ..................................................................................................... 44 1.10 MITOCHONDRIAL DISEASES ............................................................................... 47 1.10.1 Epidemiology ............................................................................................. 47 1.10.2 Classification .............................................................................................. 48 1.10.3 Clinical Manifestations .............................................................................. 52 1.10.4 Diagnostic Investigations ........................................................................... 54 1.10.5 Mitochondrial Histochemistry ................................................................... 54 1.10.6 Biochemical Studies ................................................................................... 59 1.10.7 Molecular Genetic Analysis ....................................................................... 60 1.11 GENETIC COUNSELLING ..................................................................................... 63 1.12 TREATMENTS FOR MITOCHONDRIAL DISEASE .................................................... 64 1.12.1 Supportive Measures .................................................................................. 64 1.12.2 Disease-Modifying Treatments .................................................................. 65 1.12.3 Gene Therapy ............................................................................................. 67 1.12.4 Preventing Transmission ............................................................................ 68 1.13 ANIMAL MODELS OF MITOCHONDRIAL DISEASE ............................................... 69 III 1.13.1 Autosomal Dominant Optic Atrophy ......................................................... 69 1.13.2 Leber Hereditary Optic Neuropathy .......................................................... 71 1.13.3 Chronic Progressive External Ophthalmoplegia ........................................ 72 CHAPTER 2 RESEARCH FOCUS .......................................................................... 74 2.1 AUTOSOMAL DOMINANT OPTIC ATROPHY ........................................................... 75 2.2 LEBER HEREDITARY OPTIC NEUROPATHY ........................................................... 76 2.3 CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA ..................................... 76 CHAPTER 3 DOA – CLINICAL PHENOTYPE AND MUTATIONAL SPECTRUM ................................................................................................................ 77 3.1 OPA1 IN MULTIPLE MITOCHONDRIAL DNA DELETION DISORDERS ....................... 78 3.2 GENOMIC REARRANGEMENTS IN OPA1 ARE FREQUENT IN AUTOSOMAL DOMINANT OPTIC ATROPHY .......................................................................................................... 78 3.3 OPA1 INCREASES THE RISK OF NORMAL BUT NOT HIGH TENSION GLAUCOMA ...... 78 3.4 MULTI-SYSTEM NEUROLOGICAL DISEASE IS COMMON IN PATIENTS WITH OPA1 MUTATIONS ................................................................................................................ 79 3.5 THE PREVALENCE AND NATURAL HISTORY OF DOMINANT OPTIC ATROPHY DUE TO OPA1 MUTATIONS ..................................................................................................... 79 3.6 GENETIC SCREENING FOR OPA1 AND OPA3 MUTATIONS IN PATIENTS WITH SUSPECTED INHERITED OPTIC NEUROPATHIES .......................................................... 79 3.7 PATTERN OF RETINAL GANGLION CELL LOSS IN DOMINANT OPTIC ATROPHY DUE TO OPA1 MUTATIONS ..................................................................................................... 80 IV CHAPTER 4 DOA – ANIMAL MODELS AND DISEASE MECHANISMS ...... 81 4.1 SECONDARY MTDNA DEFECTS DO NOT CAUSE OPTIC NERVE DYSFUNCTION IN A MOUSE MODEL OF DOMINANT OPTIC ATROPHY ........................................................... 82 4.2 SUBTLE NEUROLOGICAL AND METABOLIC ABNORMALITIES IN AN OPA1 MOUSE MODEL OF AUTOSOMAL DOMINANT OPTIC ATROPHY .................................................. 82 4.3 OPA1 MUTATIONS CAUSE CYTOCHROME C OXIDASE DEFICIENCY DUE TO LOSS OF WILD-TYPE MTDNA MOLECULES. .............................................................................. 82 4.4 OPA1 MUTATIONS IMPAIR MITOCHONDRIAL FUNCTION IN BOTH PURE AND COMPLICATED DOMINANT OPTIC ATROPHY ................................................................ 83 CHAPTER 5 LEBER HEREDITARY OPTIC NEUROPATHY .........................
Load more

Recommended publications
  • Call for Evidence Replies for Mitochondrial Review.Pdf
    14th of March 2011 Mitochondria Review, Policy Team, HFEA, 21 Bloomsbury Street, London. WC1B 3HF. Dear Sir/Madam, Call for evidence: Scientific review of the methods to avoid mitochondrial transfer At a previous Scientific and Clinical Advances Advisory Committee (SCAAC) meeting on the 13th of May 2010, the production of (1) pronuclear transfer-derived human embryos reaching the blastocyst stage containing on average <2 % mitochondrial DNA (mtDNA) carry-over from the original zygote and (2) spindle transfer-derived monkeys exhibiting normal development, was reported. The publication relating to the latter, reported no mtDNA carry-over1. 1. I would like to draw the core panel’s attention to the numerous somatic and embryonic cell nuclear transfer animal studies which show that mtDNA carry-over from the original cells to embryos, foetuses and offspring is a regular phenomenon2-12. Somatic and embryonic cell nuclear transfer involves transferring a nucleus from a somatic or an embryonic cell, respectively, and placing into an oocyte that has had its nucleus removed, making the techniques analogous to that of pronuclear and spindle transfer. Indeed, mtDNA carry-over has been detected in 165 out of 204 (~ 54 %) cases, with up to 59 % mtDNA carry-over reported in one offspring3. As this amount was far in excess that present immediately after the somatic cell nuclear transfer, the authors suggested the mtDNA of the original somatic cell had been preferentially amplified during development3. While these studies involved animals (not humans), transferring nuclei from somatic/embryonic cells with healthy mitochondria (not pronuclei or nuclear DNA from embryos or oocytes, respectively, with unhealthy mitochondria), they raise the strong possibility, that despite best efforts, the unhealthy mitochondria will be carried over and preferentially amplified to levels that could cause mitochondrial disease in “mitochondrial-replacement” babies.
    [Show full text]
  • Clinical Measures, Gait and Exercise in Mitochondrial Disease Jane Newman
    Clinical Measures, Gait and Exercise in Mitochondrial Disease Jane Newman Institute of Cellular Medicine Newcastle University This thesis is submitted for admission to the degree of Doctor of Philosophy at Newcastle University, UK May 2015 i Abstract Mitochondrial diseases are one of the most common forms of inherited neuromuscular disease. The presentations of these diseases are highly variable with both neurological and systemic involvement . Despite progress in identifying mitochondrial DNA mutations that result in disease, the natural history of mitochondrial diseases still remains unclear and no effective treatments are currently available (Pfeffer et al., 2012). The use of numerous primary outcomes in studies has made comparisons between studies difficult. A recent Cochrane review recommended the use of measures that were more relevant to patients in studies. This thesis aims to explore the use physiological measures alongside functional measures and gait in mitochondrial disease. The studies demonstrated that all functional outcome measures were able to discriminate between participants with mitochondrial disease and control subjects. However, gait characteristics were also able to discriminate between the two different mitochondrial genotypes. An aerobic exercise intervention resulted in an improvement in exercise capacity. However, disease severity, functional ability and gait measures remained unchanged. The main findings from this thesis are that: Clinical functional measures and gait are relevant for use in the research and clinical management of mitochondrial disease to monitor disease burden. The improvement in exercise capacity following a cycling intervention was unable to be translated into an improvement in function or gait. Therefore further research into other types of interventions, which may improve activities relevant to patients, is required.
    [Show full text]
  • The Biologist
    BIOETHICS IMMUNOLOGY BIOENGINEERING ‘ETHICS DUMPING’ IN WHAT’S CAUSING STRANGE COMPUTER-AIDED DESIGN THE LIFE SCIENCES NEW MEAT ALLERGIES? SOFTWARE FOR BIOLOGY THE MAGAZINE OF THE ROYAL SOCIETY OF BIOLOGY /www.rsb.org.uk ISSN 0006-3347 • Vol 66 No 3 • Jun/Jul 19 TURN THE TIDE A blueprint to save marine biodiversity, with Callum Roberts Volume 66 No 3 CONTENTS June/July 2019 HAVE AN IDEA FOR AN ARTICLE OR INTERESTED IN WRITING FOR US? For details contact [email protected] ROYAL SOCIETY OF BIOLOGY 1 Naoroji Street, Islington, London WC1X 0GB Tel: 020 7685 2400 [email protected]; www.rsb.org.uk EDITORIAL STAFF Editor Tom Ireland MRSB @Tom_J_Ireland ON THE COVER [email protected] 12 Interview: Callum Roberts Editorial assistant The marine biologist explains the Emma Wrake AMRSB benefits of using protected areas Chair of the Editorial Board of ocean to boost biodiversity Professor Alison Woollard FRSB Editorial Board Dr Anthony Flemming MRSB, Syngenta Professor Adam Hart FRSB, University of Gloucestershire UP FRONT Dr Sarah Maddocks CBiol MRSB, 26 04 Society News Cardiff Metropolitan University Speaker’s lecture, Teacher Professor Shaun D Pattinson FRSB, Durham University of the Year 2019 and our AGM Dr James Poulter MRSB, University of Leeds 06 Policy and analysis Dr Cristiana P Velloso MRSB, King’s College London The Government’s National Food Strategy, plus Brexit Watch Membership enquiries Tel: 01233 504804 [email protected] FEATURES Subscription enquiries Tel: 020 7685 2556; [email protected] 08 Research review The NC3Rs’ efforts
    [Show full text]
  • Trustees' Report and Financial Statements 2019-2020
    SCIENCE SHAPING THE WORLD WE LIVE IN 1 STRATEGIC REPORT STRATEGIC GOVERNANCE FINANCIAL STATEMENTS FINANCIAL OTHER INFORMATION OTHER Science Shaping the world we live in Trustees’ report and financial statements for the year ended 31 March 2020 2 THE ROYAL SOCIETY TRUSTEES’ REPORT AND FINANCIAL STATEMENTS SCIENCE SHAPING THE WORLD WE LIVE IN 3 Contents About us STRATEGIC REPORT REPORT STRATEGIC About us 3 The Royal Society’s fundamental President’s foreword 6 Executive Director’s report 8 purpose, reflected in its founding Public benefit statement 10 Charters of the 1660s, is to recognise, Charity Our strategy at a glance 12 promote and support excellence As a registered charity, the Royal Society undertakes a range of activities that provide Where our income comes from and how we spend it 14 in science and to encourage the public benefit either directly or indirectly. These include providing financial support for scientists development and use of science for at various stages of their careers, funding STRATEGY IN ACTION programmes that advance understanding of our GOVERNANCE Promoting excellence in science 16 the benefit of humanity. world, organising scientific conferences to foster How the Society has supported discussion and collaboration, and publishing the response to the pandemic 20 scientific journals. Supporting international The Society is a self-governing scientific collaboration 22 Future Leaders – Fellowship of distinguished scientists African Independent Research (FLAIR) Fellowships 26 drawn from all areas of science, Demonstrating the importance technology, engineering, mathematics The Society has of science to everyone 28 Fellowship and medicine. three roles that are Climate and biodiversity 32 As a fellowship of outstanding scientists key to performing STATEMENTS FINANCIAL embracing the entire scientific landscape, the GOVERNANCE its purpose: Society recognises excellence and elects Fellows and Foreign Members from all over the world.
    [Show full text]
  • Impact Case Study
    Impact case study (REF3b) Institution: Newcastle University Unit of Assessment: UoA-1 Title of case study: Towards prevention of mitochondrial diseases: changing government policy and influencing public debate. 1. Summary of the impact Research at Newcastle University, the only centre licenced in the UK, has shown that the in vitro fertilisation-based technique of pronuclear transfer to prevent the transmission of mitochondrial disease from mother to child is feasible. As a consequence the UK Government asked the regulator responsible, the Human Fertilisation and Embryology Authority (HFEA), to conduct both a scientific safety review of the techniques in which Newcastle research was widely referenced and to undertake a public consultation exercise. The findings from both these consultations and from a separate Nuffield Council on Bioethics report were supportive, to the extent that in June 2013 the UK’s Chief Medical Officer announced that the Government would bring forward draft legislation to change the law in the UK to allow embryos created using the Newcastle approach to be used for the treatment of affected couples. 2. Underpinning research Key researchers. Professors Mary Herbert and Douglass Turnbull of Newcastle University led the research on pronuclear transfer (PNT). Professor Alison Murdoch of the Newcastle Fertility Centre led the clinical care of the women who donated eggs. Professor Patrick Chinnery studied the likelihood of intergenerational transfer of diseased mitochondria after PNT. Background. Mitochondria provide about 90% of the body’s energy requirements and are the only cellular structures other than the nucleus that contain DNA. Each mitochondrion contains multiple copies of this DNA and each cell has many mitochondria.
    [Show full text]